SCHEMBL520347

SCHEMBL520347

Clc1cccc(-c2ccc3cnc(Nc4ccc5ncccc5c4)nn23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.45
INSR P06213 4/20 0.45
ALK Q9UM73 3/20 0.45
PTK2 Q05397 3/20 0.45
IGF1R P08069 1/20 0.41
MET P08581 1/20 0.41
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCD Q05655 1/20 0.40
TGFBR1 P36897 1/20 0.39
TGFBR2 P37173 1/20 0.39
PLK1 P53350 1/20 0.39
ULK1 O75385 1/20 0.39
ULK2 Q8IYT8 1/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
ABCB1 P08183 1/20 0.39
ABCC1 P33527 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519824 0.83 JAK2 (0.54) JAK2INSRALKPTK2IGF1R
SCHEMBL16530362 0.82 MAPT (0.42) JAK2INSRALKPTK2
SCHEMBL519419 0.81 JAK2 (0.44) JAK2INSRALKPTK2PLK1
SCHEMBL519619 0.80 JAK2 (0.48) JAK2INSRALKPTK2
SCHEMBL520994 0.79 JAK2 (0.63) JAK2INSRALKPTK2PLK1
SCHEMBL519875 0.78 JAK2 (0.64) JAK2INSRALKPTK2PLK1
SCHEMBL519534 0.78 INSR (0.48) JAK2INSRALKPTK2ULK1
SCHEMBL519729 0.78 JAK2 (0.56) JAK2INSRALKPTK2PLK1
SCHEMBL518241 0.77 JAK2 (0.68) JAK2INSRALKPTK2
SCHEMBL520434 0.77 INSR (0.65) JAK2INSRALKPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP claimed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US claimed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US claimed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP claimed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO claimed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 JAK2 1/4885INSR 1738/4885ALK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.